Clinical Trial Update: Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD [Phase 1, Phase 2]

View source ↗

Summary

A multicenter Phase 1/2 trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of SCT520FF in patients with neovascular age-relat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• SCT520FF

Snippet

Sponsor: Sinocelltech Ltd. | Conditions: nAMD | Phase 1, Phase 2 | Status: RECRUITING